Haematologica (Nov 2023)
A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and ‘on-demand’ plerixafor in multiple myeloma patients treated with novel agents
- Roberto Mina,
- Maria Teresa Petrucci,
- Francesca Bonello,
- Velia Bongarzoni,
- Riccardo Saccardi,
- Giuseppe Bertuglia,
- Andrea Mengarelli,
- Andrea Spadaro,
- Chiara Lisi,
- Paola Curci,
- Roberto Massimo Lemoli,
- Stelvio Ballanti,
- Rita Floris,
- Luca Cupelli,
- Patrizia Tosi,
- Attilio Olivieri,
- Delia Rota-Scalabrini,
- Clotilde Cangialosi,
- Chiara Nozzoli,
- Barbara Anaclerico,
- Francesca Fazio,
- Benedetto Bruno,
- Katia Mancuso,
- Paolo Corradini,
- Giuseppe Milone,
- Mario Boccadoro
Affiliations
- Roberto Mina
- Division of Hematology, AOU Citta della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino
- Maria Teresa Petrucci
- Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Rome
- Francesca Bonello
- Medical Oncology Department, Candiolo Cancer Institute, FPO-IRCCS, Candiolo
- Velia Bongarzoni
- U.O.C. Ematologia, Azienda Ospedaliera "San Giovanni/Addolorata", Roma
- Riccardo Saccardi
- Cellular Therapy and Transfusion Medicine Unit, Careggi University Hospital, Florence
- Giuseppe Bertuglia
- Division of Hematology, AOU Citta della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino
- Andrea Mengarelli
- Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome
- Andrea Spadaro
- Division of Hematology, AOU Policlinico, University of Catania
- Chiara Lisi
- Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Rome
- Paola Curci
- Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari
- Roberto Massimo Lemoli
- Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genova, Italy; IRCCS Policlinico San Martino, Genova
- Stelvio Ballanti
- Sezione di Ematologia e Immunologia Clinica, Ospedale Santa Maria della Misericordia, localita Sant’Andrea delle Fratte, Perugia
- Rita Floris
- S.C. Ematologia e CTMO, Ospedale Oncologico “A. Businco”, Cagliari
- Luca Cupelli
- Department of Hematology, S. Eugenio Hospital, Rome
- Patrizia Tosi
- Hematology Unit, Infermi Hospital, Rimini
- Attilio Olivieri
- Clinica di Ematologia, Azienda Ospedaliero Universitaria delle Marche, Ancona
- Delia Rota-Scalabrini
- Medical Oncology Department, Candiolo Cancer Institute, FPO-IRCCS, Candiolo
- Clotilde Cangialosi
- U.O.C. Ematologia, A.O. Ospedali Riuniti Villa Sofia-Cervello, Palermo
- Chiara Nozzoli
- Cellular Therapy and Transfusion Medicine Unit, Careggi University Hospital, Florence
- Barbara Anaclerico
- U.O.C. Ematologia, Azienda Ospedaliera "San Giovanni/Addolorata", Roma
- Francesca Fazio
- Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Rome
- Benedetto Bruno
- Division of Hematology, AOU Citta della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino
- Katia Mancuso
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seragnoli”, Bologna, Italy; Dipartimento di Scienze Mediche e Chirurgiche, Universita di Bologna, Bologna
- Paolo Corradini
- Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Universita di Milano, Milano
- Giuseppe Milone
- Division of Hematology, AOU Policlinico, University of Catania
- Mario Boccadoro
- Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino
- DOI
- https://doi.org/10.3324/haematol.2023.284023
- Journal volume & issue
-
Vol. 109,
no. 5
Abstract
High-dose melphalan plus autologous stem cell transplantation (ASCT) is a standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM), and adequate hematopoietic stem cell (HSC) collection is crucial to ensure hematologic recovery after ASCT. In this prospective, observational study we evaluated HSC mobilization with granulocyte colony-stimulating factor (G-CSF), cyclophosphamide, and ‘on-demand’ plerixafor (in patients with 60% (odds ratio [OR]=4.14), lenalidomide use (OR=4.45), and grade 3-4 hematologic toxicities during induction (OR=3.53) were independently associated with a higher risk of mobilization failure or plerixafor need. Cyclophosphamide plus G-CSF and ‘on-demand’ plerixafor is an effective strategy in NDMM patients treated with novel agents, resulting in a high rate of HSC collection and high HSC yield (clinicaltrials gov. identifier: NCT03406091).
